CytomX Therapeutics (CTMX) Non Operating Income (2016 - 2017)

CytomX Therapeutics' (CTMX) quarterly Non Operating Income came in at $806000.0 in Q3 2017, up 283.81% YoY from $210000.0 in Q3 2016, and up 125.77% on a QoQ basis from $357000.0 in Q2 2017.

CytomX Therapeutics (CTMX) Non Operating Income (2016 - 2017) Analysis & Trends

CytomX Therapeutics (CTMX) has 2 years of Non Operating Income data on file, last reported at $806000.0 in Q3 2017.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 234.30 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -139.24 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 12.40
7 Royalty Pharma 33.72 Bn 35.84 Bn - -51.63 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -53.64 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 CytomX Therapeutics 732.14 Mn 401.86 Mn - -

Historic Data

Download Data
DateValue
Sep 30, 2017 806,000.00
Jun 30, 2017 357,000.00
Sep 30, 2016 210,000.00
Jun 30, 2016 195,000.00